Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, Rossman R, Saibil F, Lariviere L. Sutherland LR, et al. Among authors: poleski m. Gastroenterology. 1997 Apr;112(4):1069-77. doi: 10.1016/s0016-5085(97)70117-3. Gastroenterology. 1997. PMID: 9097988 Clinical Trial.
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK. Duda DG, et al. Among authors: poleski m. Oncologist. 2010;15(6):577-83. doi: 10.1634/theoncologist.2010-0029. Epub 2010 May 18. Oncologist. 2010. PMID: 20484123 Free PMC article. Clinical Trial.
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK. Willett CG, et al. Among authors: poleski m. Oncologist. 2010;15(8):845-51. doi: 10.1634/theoncologist.2010-0030. Epub 2010 Jul 28. Oncologist. 2010. PMID: 20667969 Free PMC article. Clinical Trial.
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Willett CG, et al. Among authors: poleski m. J Clin Oncol. 2009 Jun 20;27(18):3020-6. doi: 10.1200/JCO.2008.21.1771. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470921 Free PMC article. Clinical Trial.
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK. Willett CG, et al. Among authors: poleski m. Nat Clin Pract Oncol. 2007 May;4(5):316-21. doi: 10.1038/ncponc0813. Nat Clin Pract Oncol. 2007. PMID: 17464339 Free PMC article.
The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review.
Wild D, Sung AD, Cardona D, Cirricione C, Sullivan K, Detweiler C, Shealy M, Balmadrid B, Rowes KL, Chao N, Piryani S, Karimabad HM, Martin P, Poleski M. Wild D, et al. Among authors: poleski m. Dig Dis Sci. 2016 Mar;61(3):806-13. doi: 10.1007/s10620-015-3938-8. Epub 2015 Nov 4. Dig Dis Sci. 2016. PMID: 26537485 Free PMC article.
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK. Xu L, et al. Among authors: poleski m. Cancer Res. 2009 Oct 15;69(20):7905-10. doi: 10.1158/0008-5472.CAN-09-2099. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826039 Free PMC article.
Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD. Coutré SE, et al. Among authors: poleski mh. Leuk Lymphoma. 2015;56(10):2779-86. doi: 10.3109/10428194.2015.1022770. Epub 2015 May 19. Leuk Lymphoma. 2015. PMID: 25726955 Free PMC article. Review.
23 results